No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
Truxima (rituximab biosimilar)
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
Rixathon (rituximab biosimilar)
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
Ruxience (rituximab biosimilar)
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
CD20 positive
CD20 positive
|
Follicular Lymphoma
Follicular Lymphoma
|
rituximab + ibritumomab tiuxetan
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
EZH2 mutation
EZH2 mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
CD20 positive
CD20 positive
|
Follicular Lymphoma
Follicular Lymphoma
|
Ruxience (rituximab biosimilar)
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
R-CHOP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
R-CVP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
rituximab + obinutuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
lenalidomide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
chlorambucil
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
lenalidomide + obinutuzumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
cyclophosphamide oral
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
G-CHOP
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
tisagenlecleucel-T
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
CG-781
Sensitive: B - Late Trials
|
BCL2 elevation + IGH elevation
BCL2 elevation + IGH elevation
|
Follicular Lymphoma
Follicular Lymphoma
|
rituximab
Resistant: B - Late Trials
|
No biomarker
No biomarker
|
Follicular Lymphoma
Follicular Lymphoma
|
INCB50465
Sensitive: B - Late Trials
|
CD20 positive
CD20 positive
|
Follicular Lymphoma
Follicular Lymphoma
|
Truxima (rituximab biosimilar)
Sensitive: C1 - Off-label
|
CD20 positive
CD20 positive
|
Follicular Lymphoma
Follicular Lymphoma
|
GEN3013
Sensitive: C2 – Inclusion Criteria
|
BCL2 mutation
BCL2 mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
|
CXCL11 elevation
CXCL11 elevation
|
Follicular Lymphoma
Follicular Lymphoma
|
duvelisib
Resistant: C3 – Early Trials
|
IL2RA elevation
IL2RA elevation
|
Follicular Lymphoma
Follicular Lymphoma
|
duvelisib
Resistant: C3 – Early Trials
|
Chr del(6q)(q15)
Chr del(6q)(q15)
|
Follicular Lymphoma
Follicular Lymphoma
|
duvelisib
Sensitive: C3 – Early Trials
|
EZH2 mutation
EZH2 mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
rituximab
Resistant: C3 – Early Trials
|
KMT2D mutation
KMT2D mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
R-CHOP
Resistant: C3 – Early Trials
|
ARID1B mutation
ARID1B mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
R-CHOP
Resistant: C3 – Early Trials
|
BCL7A mutation
BCL7A mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
R-CHOP
Resistant: C3 – Early Trials
|
TNFAIP3 mutation
TNFAIP3 mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
R-CHOP
Resistant: C3 – Early Trials
|
GNA13 mutation
GNA13 mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
R-CHOP
Sensitive: C3 – Early Trials
|
|
Follicular Lymphoma
Follicular Lymphoma
|
R-CHOP
Sensitive: C3 – Early Trials
|
GNA12 mutation
GNA12 mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
R-CHOP
Sensitive: C3 – Early Trials
|
PLCG2 mutation
PLCG2 mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
R-CHOP
Resistant: C3 – Early Trials
|
|
Follicular Lymphoma
Follicular Lymphoma
|
rituximab
Sensitive: C3 – Early Trials
|
FCGR2A mutation
FCGR2A mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
rituximab + lenalidomide
Sensitive: C3 – Early Trials
|
TBX21 overexpression
TBX21 overexpression
|
Follicular Lymphoma
Follicular Lymphoma
|
nivolumab + ibrutinib
Sensitive: C3 – Early Trials
|
LDH elevation
LDH elevation
|
Follicular Lymphoma
Follicular Lymphoma
|
ViPOR
Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL6 rearrangement
MYC rearrangement + BCL6 rearrangement
|
Follicular Lymphoma
Follicular Lymphoma
|
EPOCH-R
Resistant: C3 – Early Trials
|
MYC rearrangement
MYC rearrangement
|
Follicular Lymphoma
Follicular Lymphoma
|
EPOCH-R
Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
MYC rearrangement + BCL2 rearrangement
|
Follicular Lymphoma
Follicular Lymphoma
|
EPOCH-R
Sensitive: C3 – Early Trials
|
MYC rearrangement + BCL2 rearrangement
MYC rearrangement + BCL2 rearrangement
|
Follicular Lymphoma
Follicular Lymphoma
|
R-DHAP
Sensitive: C3 – Early Trials
|
|
Follicular Lymphoma
Follicular Lymphoma
|
nivolumab
Sensitive: C3 – Early Trials
|
CD20 positive
CD20 positive
|
Follicular Lymphoma
Follicular Lymphoma
|
MB-106
Sensitive: C3 – Early Trials
|
HAVCR2 expression
HAVCR2 expression
|
Follicular Lymphoma
Follicular Lymphoma
|
venetoclax + atezolizumab + obinutuzumab
Sensitive: C3 – Early Trials
|
|
Follicular Lymphoma
Follicular Lymphoma
|
venetoclax
Resistant: C4 – Case Studies
|
CREBBP mutation
CREBBP mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
YF2
Sensitive: D – Preclinical
|
TP53 mutation
TP53 mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
YF2
Sensitive: D – Preclinical
|
EZH2 mutation
EZH2 mutation
|
Follicular Lymphoma
Follicular Lymphoma
|
CPI-169
Sensitive: D – Preclinical
|
TBX21 expression
TBX21 expression
|
Follicular Lymphoma
Follicular Lymphoma
|
nivolumab + ibrutinib
Sensitive: D – Preclinical
|
